{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053341","form_type":"8-K","ticker":"GRAL","cik":"0001699031","company_name":"GRAIL, Inc.","filed_at":"2026-08-05T20:08:32+00:00","discovered_at":"2026-08-05T20:10:13.884978+00:00","generated_at":"2026-08-05T20:11:25.672177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRAIL Q2 2026 revenue up 26% to $44.7M; Galleri volume up 35% YoY; net loss $110.2M","bullets":["Total revenue $44.7M (+26% YoY); Galleri test revenue $42.6M (+24% YoY); test volume >61,000 (+35% YoY).","Net loss $110.2M, improved $3.7M (3%) YoY; gross loss $12.6M, improved 29%.","Non-GAAP adjusted gross profit $21.6M (+34% YoY); adjusted EBITDA -$90.3M.","Completed $110M equity financing with Samsung; PMA submitted, FDA advisory committee expected in fall.","Presented NHS-Galleri and PATHFINDER 2 results at ASCO 2026, showing consistent performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053341","json":"https://secwatch.observer/filing/0001628280-26-053341.json","markdown":"https://secwatch.observer/filing/0001628280-26-053341.md","text":"https://secwatch.observer/filing/0001628280-26-053341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/0001628280-26-053341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/gral-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:11:25.672177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}